Developing next generation treatments to preserve vision for patients with diseases affecting the back of the eye

OXURION to Participate in Upcoming Investor Meetings

7 Jan 2021

Leuven, BELGIUM, Boston, MA, US - January 7, 2021 – 08.00 AM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care ophthalmic therapies, with a focus on diabetic macular edema (DME), today announces its management will participate and meet with investors at the following upcoming virtual meetings: 

H.C. Wainwright Bioconnect 2021 Conference
January 11 – 14, 2021
CEO Company presentation scheduled on January 11 at 12.00 PM CET
BIO Partnering at JPM Week
January 11 – 15, 2021
BIOTECH Showcase @JPM Week 2021
January 11 – 15, 2021
CEO Company presentation
Access China Forum @JPM Week 2021
January 4 – 22, 2021
CEO company presentation on January 7th at 9.20 AM
Degroof Petercam Healthcare Conference
January 26 – 28, 2021
BIOMED Event by Invest Securities
January 26 -27, 2021

 

For more information, please visit Oxurion’s events page.

Press release attachment: 
Tags: 
Company; THR-149; THR-687; Investors